Trimel Announces Exclusive License Agreement With Endo
Trimel Pharmaceuticals Corporation recently announced the signing of an agreement by its subsidiary, Trimel Biopharma SRL, providing an affiliate of Endo International plc with the exclusive rights to market NATESTO in the United States and Mexico. NATESTO is the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism.
Under the terms of the agreement, Trimel is eligible to receive payments of up to $165 million based on certain regulatory and sales milestones in addition to an upfront fee of $25 million and a prepaid inventory deposit of $5 million upon closing of the deal. Additionally, Trimel will be responsible for the manufacture of NATESTO and receive a tiered supply price for the product. Closing of the transaction is subject to customary Hart-Scott-Rodino approval.
“We are delighted to announce this partnership agreement with Endo as it represents another significant achievement for our company and an opportunity to capture the value we have created in developing NATESTO,” said Tom Rossi, President and CEO of Trimel. “Endo is a leader in the US men’s healthcare and urology segments, making them the ideal partner for NATESTO. We look forward to working with Endo as they prepare to launch this innovative and differentiated treatment option for patients suffering from low testosterone.”
Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health, and respiratory medicine. For more information, visit www.trimelpharmaceuticals.com.
Endo International plc is a global specialty healthcare company focused on improving patients’ lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic, and device products through its operating companies. For more information, visit www.endo.com.
Total Page Views: 892
